



IDT Biologika breaks ground for its new research building

Forward-looking investment and sophisticated jobs in Riems

Riems, 5/26/15 – **IDT Biologika (Riems) has launched a significant expansion project with a new laboratory building for research and quality control. “With today's groundbreaking, IDT demonstrates the extensive investments it is committing to prepare the Riems site for the future. Riems is becoming a central component of IDT, for both its cutting-edge research and state-of-the-art vaccine production,” said Dr. Ralf Pfirmann, CEO of IDT Biologika.**

In her welcome speech, district representative for the German Bundestag Dr. Angela Merkel called IDT Biologika a “hidden champion” in worldwide innovation, known only to the experts. State Secretary of the Mecklenburg-Western Pomerania Economy Ministry Dr. Stefan Rudolph explained at the ceremony that IDT will soon have a presence in Mecklenburg-Western Pomerania with all the activities along the vaccine production chain.

With the takeover of the Riems site by IDT Biologika in autumn 2013, IDT Biologika (Riems) became an integral part of the company's vaccine production process. Research in the field of animal health also begun again immediately upon the company's launch. The new site's geographic proximity strengthens the intensive relationships that have existed for many years between the Friedrich Loeffler Institute and IDT Biologika.

27 laboratories being built

The necessary expansion of the IDT site in Riems for research and vaccine production is being achieved with an investment of some €12 million. The German state of Mecklenburg-Western Pomerania is supporting the project with a 25% grant. The project's broad political support was clearly shown at the groundbreaking ceremony in speeches by Dr. Angela Merkel and Economy Secretary Dr. Stefan Rudolph. State parliamentary representative Egbert Liskow and Greifswald Mayor Dr. König have also visited IDT Biologika.

“The primary project is the new building for research and quality control, which will contain a total of 27 laboratories for both types of tasks,” reported Dr. Jörg Köhler, Managing Director of IDT Biologika (Riems). “Two of the twelve laboratories for biosafety level BSL3 research will be located here. Four specialized laboratories for both areas will meet Good Manufacturing Practice (GMP) requirements for drug manufacture.”

The new laboratory building with a total of 1,800 square meters should be completed by the end of 2016, with certification of the laboratories by mid-2017. “The site's manufacturing and logistics infrastructure is also being modernized, with an investment of some €2 million, primarily aimed at renovating existing buildings,” added Dr. Köhler.

Riems as a scientific and industrial site

“With the global demand for our expertise and capacities, IDT Biologika's dynamic growth ensures a high rate of production of animal health vaccines for the Riems site. Riems is thus overall becoming a site for both science and industry, intensely dedicated to fighting zoonoses, infectious diseases that can be passed from animals to humans,” said IDT CEO Dr. Ralf Pfirmann. “We are making a significant contribution to this process, which the new building will make visible for everyone.

Ground is being broken today so that in the future we can create targeted, sophisticated jobs. This will play an important role for this region. We hope that the development of the Riems IDT site proceeds as planned so that our growth can continue, and we are grateful for the broad support of the state of Mecklenburg-Western Pomerania and the city of Greifswald.”

“IDT in Riems will contribute to enhancing IDT's globally recognized expertise in fighting diseases in people and animals with new, high-caliber and effective vaccines. We are creating the necessary conditions for this now,” concluded Dr. Pfirmann.

IDT Biologika in Riems

IDT Biologika (Riems) GmbH & Co KG is a subsidiary of IDT Biologika GmbH situated in Riems-Greifswald. The company currently has 60 employees focused on researching and producing vaccines for veterinary medicine applications.

About IDT Biologika

IDT Biologika is an innovative, privately-held company with more than 90 years of experience in researching, developing, manufacturing and marketing products for human and animal health.

Company sites in Germany include the BioPharmaPark in Dessau and Greifswald. The IDT sales offices in the US, Denmark, the Netherlands, France and Spain are focused on the animal health business segment.

In 2014, IDT Biologika achieved sales of around €172 million in the animal health, vaccine and pharmaceutical business segments, as well as quality control (provisional figure before formal closure of the annual accounts). Around 1,250 employees currently work at IDT Biologika.

IDT Biologika and IDT Biologika Riems are members of the Klocke Group.

Klocke Holding

IDT Biologika is a company of the Klocke Holding Group. The Klocke Holding Group companies specialize in contract manufacturing and packaging of pharmaceuticals, vaccines, and cosmetic products. With more than 1,800 employees at six locations in Europe and the USA, the traditionally family-owned Klocke Group offers comprehensive services for production and packaging of pharmaceutical products.

Contact

IDT Biologika
Corporate Communication
Peter Kellner
Am Pharmapark
06861 Dessau, Germany
Tel: +49 34901 885 5681
Fax: +49 34901 885 5323
Mobile +49 162 4248453
Email: peter.kellner@idt-biologika.de
Website: www.idt-biologika.de